CN116790431A - 能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用 - Google Patents
能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用 Download PDFInfo
- Publication number
- CN116790431A CN116790431A CN202310741822.4A CN202310741822A CN116790431A CN 116790431 A CN116790431 A CN 116790431A CN 202310741822 A CN202310741822 A CN 202310741822A CN 116790431 A CN116790431 A CN 116790431A
- Authority
- CN
- China
- Prior art keywords
- aui2301
- bifidobacterium animalis
- diarrhea
- lactis
- constipation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 32
- 206010010774 Constipation Diseases 0.000 title claims abstract description 31
- 241001134770 Bifidobacterium animalis Species 0.000 title claims abstract description 26
- 229940118852 bifidobacterium animalis Drugs 0.000 title claims abstract description 26
- 230000000813 microbial effect Effects 0.000 title claims abstract description 15
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000002858 neurotransmitter agent Substances 0.000 claims description 6
- 239000006041 probiotic Substances 0.000 claims description 5
- 235000018291 probiotics Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 230000002964 excitative effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000002054 inoculum Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract description 13
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract description 13
- 229940022698 acetylcholinesterase Drugs 0.000 abstract description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 13
- 230000013872 defecation Effects 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 10
- 230000002829 reductive effect Effects 0.000 abstract description 10
- 210000000056 organ Anatomy 0.000 abstract description 7
- 241000218588 Lactobacillus rhamnosus Species 0.000 abstract description 6
- 229940009289 bifidobacterium lactis Drugs 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 26
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 17
- 239000003833 bile salt Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 12
- 206010018910 Haemolysis Diseases 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 206010016100 Faeces discoloured Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940093761 bile salts Drugs 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013350 formula milk Nutrition 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000000035 biogenic effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 2
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 229960002983 loperamide hydrochloride Drugs 0.000 description 2
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002068 microbial inoculum Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960003732 tyramine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010014095 Histidine decarboxylase Proteins 0.000 description 1
- 102100037095 Histidine decarboxylase Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010048581 Lysine decarboxylase Proteins 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000006781 columbia blood agar Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及微生物领域,尤其涉及能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用。本发明提供了动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)AUI2301,其保藏编号为:CGMCC No.26770。本发明的AUI2301来源于中国健康婴儿的粪便,属于婴幼儿肠道的优势菌种之一。在便秘模型中,AUI2301能够显著缩短首次排黑便时间,并回调乙酰胆碱脂酶水平;在腹泻模型中,干预第二天即可显著降低腹泻评分并降低盲肠器官指数;在两个模型中的效果优于目前广泛应用的鼠李糖乳杆菌LGG。
Description
技术领域
本发明涉及微生物领域,尤其涉及能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用。
背景技术
肠道微生物在维持宿主健康中发挥重要作用,大量共生细菌在胃肠道内寄居、繁殖,并对维持最佳的宿主生理生化代谢过程具有至关重要的影响。微生物菌群通过直接抵御入侵微生物或协调合适的免疫应答以保护宿主免受感染。随着人们生活工作压力的增加,饮食结构的改变,以及过度服用抗生素药物等外界因素,导致人体肠道微生物的组成和代谢活动发生改变,从而影响宿主肠道微生物的结构和健康。
便秘是一种常见的胃肠道疾病,主要表现为排便次数少,排便困难和粪便干硬等。目前认为便秘的发生于肠道神经系统功能性障碍,内脏高敏感性,胃肠动力减慢等多种因素有关。
抗生素相关性腹泻(AAD)是一种肠道菌群失调疾病,主要是由于长期使用抗生素引起。据统计,在接受抗生素治疗的患者中,约有5%至39%的患者可能出现轻至中度腹泻。AAD的主要机制包括破坏肠道屏障、影响免疫平衡、破坏肠道微生物组的正常组成以及改变肠道代谢产物。
双歧杆菌是婴儿胃肠道的主要成员之一,作为益生菌,它可以通过调整肠道菌群、代谢产生短链脂肪酸、缓解炎症反应、增强结肠蠕动、增强肠道屏障的稳定性等来保护肠道,同时释放肠道神经递质和肠道免疫反应物质来调节肠道运动,此外,益生菌还能够缓解腹泻状态,修复器官损伤。
发明内容
有鉴于此,本发明提供了能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用。本发明的动物双歧杆菌乳亚种AUI2301(保藏编号为CGMCCNO.26770)来源于中国健康婴儿的粪便,属于婴幼儿肠道的优势菌种之一。在便秘模型中,AUI2301能够显著缩短首次排黑便时间,并回调乙酰胆碱脂酶水平;在腹泻模型中,干预第二天即可显著降低腹泻评分并降低盲肠器官指数;在两个模型中的效果优于目前广泛应用的鼠李糖乳杆菌GG(Lacticaseibacillus rhamnosus GG,LGG)。动物双歧杆菌AUI2301可用于制备能够治疗或预防便秘和抗生素相关性腹泻的食品或药品,特别可用于具有干预或治疗便秘和抗生素相关性腹泻的婴幼儿奶粉中。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis),其保藏编号为:CGMCC No.26770。
本发明还提供了微生物菌剂,包括上述动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)以及可接受的助剂。
本发明还提供了上述动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或上述微生物菌剂在制备干预和/或治疗功能性便秘的产品中的应用。
在本发明的一些实施方案中,上述应用中,所述动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)和/或所述微生物菌剂改善排便状态和/或缩短排便时间。
在本发明的一些实施方案中,上述应用中,所述动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)和/或所述微生物菌剂促进兴奋性神经递质AchE的分泌和/或降低抑制性神经递质NO的分泌。
在本发明的一些实施方案中,上述应用中,所述动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)和/或所述微生物菌剂松弛平滑肌和/或促进胃肠道运动。
本发明还提供了上述动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或上述微生物菌剂在制备干预和/或治疗抗生素相关腹泻的产品中的应用。
在本发明的一些实施方案中,上述应用中,所述动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)和/或所述微生物菌剂缓解腹泻状态和/或与所述抗生素相关腹泻的器官的损伤。
本发明还提供了产品,包括上述动物双歧杆菌乳亚种(Bifidobacteriumanimalis subsp.lactis)和/或上述微生物菌剂以及可接受的助剂或辅料。
在本发明的一些实施方案中,上述产品中,包括:益生菌制品。
在本发明的一些实施方案中,上述产品中,所述益生菌制品包括:发酵乳、乳饮料、活菌制剂和/或发酵果蔬饮料中的一种或多种。
本发明提供了动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis),其保藏编号为:CGMCC No.26770。
本发明的有益效果包括:
(1)本发明的动物双歧杆菌乳亚种AUI2301(保藏编号为CGMCC NO.26770)来源于中国健康婴儿的粪便,属于婴幼儿肠道的优势菌种之一。在便秘模型中,AUI2301能够显著缩短首次排黑便时间,并回调乙酰胆碱脂酶水平;在腹泻模型中,干预第二天即可显著降低腹泻评分并降低盲肠器官指数;在两个模型中的效果优于目前广泛应用的鼠李糖乳杆菌GG(Lacticaseibacillus rhamnosus GG,LGG)。动物双歧杆菌乳亚种AUI2301可用于制备能够治疗或预防便秘和抗生素相关性腹泻的食品或药品,特别可用于具有干预或治疗便秘和抗生素相关性腹泻的婴幼儿奶粉中。
(2)本发明的动物双歧杆菌乳亚种AUI2301具有较好的耐酸和耐胆盐能力、免疫调节能力。体内动物实验表明,本发明的动物双歧杆菌乳亚种AUI2301具有干预或治疗便秘的能力,具有干预或治疗抗生素相关性腹泻的能力,可用于发酵乳,乳酸菌饮料等食品、功能性食品与药品的生产中。
生物保藏说明
生物材料:AUI2301;分类命名:动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis);于2023年03月09日保藏于中国微生物菌种保藏管理委员会普通微生物中心;地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所;保藏编号:CGMCCNo.26770。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示实施例4中AUI2301产生物胺能力测定的图片;其中:A示AUI2301实验组、B示LGG对照组、C示金黄色葡萄球菌;其中:①示组氨酸脱羧酶;②示赖氨酸脱羧酶、③示酪氨酸脱羧酶、④示鸟氨酸脱羧酶;
图2示AUI2301实验组和LGG对照组的溶血能力测定图片;其中:左示AUI2301,右示LGG;
图3示空白组、模型组、LGG对照组和s59实验组(即为本发明AUI2301菌株)的便秘型小鼠血清中一氧化氮(NO)的含量;
图4示空白组、模型组、LGG对照组和s59实验组(即为本发明AUI2301菌株)的便秘型小鼠血清中乙酰胆碱酯酶(AchE)的含量;
图5示空白组、模型组、LGG对照组和s59实验组(即为本发明AUI2301菌株)的腹泻型小鼠的粪便含水量;
图6示空白组、模型组、LGG对照组和s59实验组(即为本发明AUI2301菌株)的腹泻型小鼠的盲肠器官指数;
图7示本发明菌株的镜检图;
图8示本发明菌株的菌落图。
具体实施方式
本发明公开了能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用。
应该理解,表述“……中的一种或多种”单独地包括每个在所述表述后叙述的物体以及所述叙述的物体中的两者或更多者的各种不同组合,除非从上下文和用法中另有理解。与三个或更多个叙述的物体相结合的表述“和/或”应该被理解为具有相同的含义,除非从上下文另有理解。
术语“包括”、“具有”或“含有”,包括其语法同义语的使用,通常应该被理解为开放性和非限制性的,例如不排除其他未叙述的要素或步骤,除非另有具体陈述或从上下文另有理解。
应该理解,只要本发明仍可操作,步骤的顺序或执行某些行动的顺序并不重要。此外,两个或更多个步骤或行动可以同时进行。
本文中的任何和所有实例或示例性语言如“例如”或“包括”的使用,仅仅打算更好地说明本发明,并且除非提出权利要求,否则不对本发明的范围构成限制。本说明书中的任何语言都不应解释为指示任何未要求保护的要素对于本发明的实践是必不可少的。
此外,用以界定本发明的数值范围与参数皆是约略的数值,此处已尽可能精确地呈现具体实施例中的相关数值。然而,任何数值本质上不可避免地含有因个别测试方法所致的标准偏差。因此,除非另有明确的说明,应当理解本公开所用的所有范围、数量、数值与百分比均经过“约”的修饰。在此处,“约”通常是指实际数值在一特定数值或范围的正负10%、5%、1%或0.5%之内。
本实施例采用传统涂布平板分离法从采集的样品中分离乳酸菌,通过模拟人体胃肠道的环境来筛选具有耐酸与耐胆盐能力的菌株,确保其可到达胃肠道中,从而进一步探究其对肠道疾病的治疗作用。功能性便秘小鼠通过灌胃盐酸洛哌丁胺进行造模,抗生素相关性腹泻小鼠通过灌胃盐酸林可霉素进行造模。
本发明目的是提供一株能够干预或治疗便秘和抗生素相关性腹泻的动物双歧杆菌;
本发明通过以下步骤获得动物双歧杆菌AUI2301:
本发明提供的AUI2301菌株(保藏编号为CGMCC No.26770)与s59菌株与为同一株菌株;
通过改良MRS培养基从新鲜婴儿粪便中分离双歧杆菌;
通过对分离株进行人工胃液耐受性和耐胆盐测试,获得良好耐受性菌株;
通过对AUI2301进行抗生素耐药性测试,产生物胺能力测试和溶血性测试,获得安全性菌株;
利用动物模型研究AUI2301对功能性便秘和抗生素相关性腹泻的干预或治疗作用。
本发明中,相关试剂及培养基配方:
改良MRS培养基:称取牛肉膏10.0g,酵母浸膏5.0g,蛋白胨10.0g,葡萄糖20.0g,醋酸钠5.0g,吐温-80 1mL,K2HPO42.0 g,柠檬酸三铵2.0g,MgSO4·7H2O 0.20g,MnSO4·4H2O0.05g,蒸馏水1000mL,121℃灭菌15min,冷却备用,使用前加入200μL/10mL半胱氨酸盐酸盐溶液和100μL/10mL莫匹罗星。
生理盐水:9.0g的Nacl溶于1000mL蒸馏水中,121℃灭菌15min,冷却备用。
墨汁:取10.0g阿拉伯胶,加少量水煮沸,后加入5.0g活性炭至上述溶液中煮沸三次,待冷却后定容到100mL,放入4℃冰箱冷藏备用,用前摇匀。
人工胃液的配制:分别取0.5g NaCl和0.3g胃蛋白酶溶解于去离子水中并定容至100mL,用1.0mol/L的盐酸调pH至2.5,0.22μm滤膜过滤除菌,4℃冰箱冷藏备用。
模拟胆盐的配制:称取一定量的胆盐于MRS液体培养基中,使其胆盐浓度(w/v)为0.075%、0.1%,调节pH至6.5±0.2,121℃灭菌15min,冷却备用。
模拟肠液配制方法:称取0.1%胰蛋白酶和0.075%或0.1%胆盐溶解于PBS,用0.1mol/L NaOH调pH至8.0,0.22μm滤膜过滤除菌,4℃冰箱冷藏备用。
AUI2301菌悬液的制备:将活化好的动物双歧杆菌AUI2301,37℃静置厌氧培养24h后,6000r/min离心10min,用无菌生理盐水洗涤离心两次后获得菌泥,用PBS溶液调整活菌数为1.0×109CFU/mL。
LGG对照组菌悬液的制备:将活化好的鼠李糖乳杆菌(LGG),37℃静置培养24h后,6000r/min离心10min,用无菌生理盐水洗涤离心两次后获得菌泥,用PBS溶液调整活菌数为1.0×109CFU/mL。
实验动物为SPF级3-4周龄KM小鼠,购于济南朋悦实验动物繁殖有限公司;测定的一氧化氮(NO)、乙酰胆碱酯酶(AchE)水平用购自于上海酶联生物科技有限公司的试剂盒,胆盐购自于北京索莱宝科技有限公司;胰蛋白酶和胃蛋白酶自于生工生物工程(上海)股份有限公司。
本发明实施例1~实施例7中,所用原料及试剂均可由市场购得。
下面结合实施例,进一步阐述本发明:
实施例1样品采集
专业人员在婴儿排便时间守候,采集4g左右的婴儿新鲜粪便中心样品置于装有30%体积分数甘油的10mL无菌离心管中,加入灭菌液体石蜡油密封。
实施例2双歧杆菌的分离
将实施例1获得的婴儿新鲜粪便样品稀释至10-2、10-3和10-4稀释度,倾注于改良MRS培养基中,于37℃厌氧培养48h,每个平板挑选3-4个菌落,形态不同、具有典型乳酸菌菌落形态特征且有溴甲酚紫变色(变黄)反应的单菌落,随后在含0.3%溴甲酚紫的改良MRS琼脂培养基上进行纯化和产酸复筛,直至得到纯化的单菌落。
实施例3AUI2301的耐受消化应激能力试验
将活化好的AUI2301取1.0mL菌悬液分别接种至9.0mL 0.075%胆盐浓度的改良MRS培养基中,于37℃厌氧培养,分别在0h和3h用平板计数法测定活菌数;
将活化好的AUI2301取1.0mL菌悬液分别接种至9.0mL 0.1%胆盐浓度的改良MRS培养基中,于37℃厌氧培养,分别在0h和3h用平板计数法测定活菌数;
AUI2301活化至2代,取1.0mL AUI2301菌悬液接种至9.0mL的pH 2.5人工胃液,于37℃厌氧培养,分别在0h和3h利用平板计数法测定活菌数;
根据公式计算存活率:
存活率(%)=应激后的活菌数/初始活菌数×100%,如表1所示,菌株AUI2301对0.075%胆盐、0.1%胆盐均具有良好耐受性,处理3h后存活率均在60%以上;同时,该菌对人工胃液也表现出良好的耐受性,存活率高达79.13%。
表1AUI2301耐酸耐胆盐能力
菌株名称 | 0.075%胆盐 | 0.1%胆盐 | 人工胃液 |
处理前活菌数(108CFU/mL) | 15.17±1.02 | 15.17±1.02 | 15.17±1.02 |
处理前活菌数(108CFU/mL) | 11.87±0.57 | 9.23±0.68 | 8.47±0.03 |
存活率(%) | 78.24±3.75 | 60.88±4.49 | 79.13±4.21 |
实施例4AUI2301的安全性评价
(1)抗生素耐药性评价
吸取100μL菌悬液(用无菌PBS调节OD600至0.6)均匀涂布于20mL已凝固的改良MRS琼脂培养基表面,待菌液完全吸收后,用无菌镊子将药敏纸片贴于培养基表面,静置30min后转移至37℃倒置厌氧培养18~24h,待抑菌圈出现后立即取出测量直径。使用LGG作为对照菌株。
表2AUI2301抗生素耐药性
注:S:敏感(sensitivity);I:中介(insensitive);R:耐药(resistant)
由表2可知,AUI2301对大多数抗生素敏感,对四环素和环丙沙星表现中介,对链霉素表现出耐药。
(2)AUI2301产生物胺能力测定
取活化2代的AUI2301菌悬液分别划线于添加了相应前体氨基酸的氨基酸脱羧酶检测培养基,37℃倒置厌氧培养48h后观察平板颜色变化,若无颜色变化则结果为阴性,若平板变紫则结果为阳性。以LGG和金黄色葡萄球菌作为对照菌株。
表3AUI2301产生物胺能力
菌株名称 | 组胺 | 尸胺 | 酪胺 | 腐胺 |
AUI2301 | - | - | - | - |
LGG | - | - | - | - |
金黄色葡萄球菌 | - | + | + | + |
由表3和图1可知,AUI2301不产生组胺、尸胺、酪胺、腐胺。
(3)AUI2301溶血性测试
取活化2代的AUI2301菌悬液划线于哥伦比亚血琼脂平板,37℃倒置厌氧培养48h后观察单菌落周围颜色变化。以LGG作为对照菌株,若单菌落周围出现草绿色圈,为α溶血,若单菌落周围出现透明圈则为β溶血,若菌落周围无颜色变化为γ溶血,即不溶血。
表4AUI2301的溶血性
菌株名称 | 溶血结果 |
AUI2301 | 不溶血 |
LGG | 不溶血 |
由表4和图2可知,AUI2301不溶血。
实施例5AUI2301对功能性便秘小鼠的影响
(1)动物分组和建立功能性便秘模型的方法:
昆明小鼠适应性喂养一周后,分为4组,每组8只。鼠李糖乳杆菌(LGG)对照组,模型组,AUI2301实验组(活化2代)连续造模7天(10μL/g,一天一次)灌胃盐酸洛哌丁胺(10mg/kgBW)。建立便秘模型后,空白组和模型对照组灌相同剂量的无菌生理盐水,鼠李糖乳杆菌(LGG)对照组和AUI2301实验组灌相同剂量的含该组受试菌的菌悬液,连续干预14天(10μL/g,一天一次)。
(2)对功能性便秘小鼠排便和小肠运动功能的影响:
在实验结束后,禁食不禁水16小时,将每组中的4只小鼠单独放入笼子里,各组灌胃洛哌丁胺10mg/kg诱导小鼠功能性便秘模型,30min后实验组给予含菌的墨汁,空白组和模型组给予空白墨汁。以灌墨汁后开始,记录各小鼠首次排黑便时间以及6h排黑便粒数和重量。其余4只各组灌胃洛哌丁胺10mg/kg诱导小鼠功能性便秘模型,LGG对照组和AUI2301实验组给予含对应菌株的墨汁,空白组和模型组给予空白墨汁。给予墨汁后25min小鼠脱颈椎处死,迅速取出幽门至盲肠部分的肠道,不改变肠道长度的情况下拉直,计算墨汁推进率。
墨汁推进率=L1/L0×100%
式中:L1(cm)为墨汁推进长度;L0(cm)为幽门到盲肠的长度。
表5AUI2301对小鼠排便和小肠运动功能的影响
注:不同字母表示具有差异性(p<0.05)
结果如表5所示,与空白组相比,模型组小鼠首次排黑便时间显著延长(p<0.01),6h拍黑便粒数减少(p<0.05),墨汁推进率降低(p<0.01),说明小鼠造模成功。与模型组相比,给予动物双歧杆菌AUI2301干预后,其首次排黑便时间缩短(p<0.01),6h排黑便粒数增加(p<0.05),墨汁推进率升高(p<0.01);与LGG对照组相比,均无显著差异,说明本发明菌株AUI2301可以改善便秘小鼠的排便状态,肠运动状态。
(3)对功能性便秘小鼠血清神经递质表达水平的影响
结果如图3、图4和表6所示,与空白组相比,模型组小鼠血清中的AchE水平显著降低(p<0.01),NO水平显著升高(p<0.01)。与模型组相比,动物双歧杆菌AUI2301干预后的小鼠血清中AchE水平显著增高(p<0.01),NO水平显著降低(p<0.01);与空白组相比,AUI2301的AchE水平无显著差异,而NO水平也接近正常水平。因此菌株AUI2301能够促进兴奋性神经递质AchE的分泌,降低抑制性神经递质NO的含量,说明本发明菌株AUI2301能够松弛平滑肌,促进胃肠道运动。
表6AUI2301对NO和AchE表达水平的影响
组别 | NO(μmol/L) | AchE(nmol/L) |
空白组 | 30.40±1.46c | 155.43±3±7.16a |
模型组 | 43.33±0.98a | 86.42±19.80c |
LGG对照组 | 33.88±2.15b | 119.92±16.39b |
AUI2301实验组 | 34.56±1.84b | 139.42±3.79ab |
实施例6AUI2301对抗生素相关性腹泻小鼠的影响
(1)动物分组和建立抗生素相关性腹泻小鼠的方法
昆明小鼠适应性喂养一周后,分为4组,每组8只。鼠李糖乳杆菌(LGG)对照组,模型组,AUI2301实验组(活化2代)连续造模3天(10μL/g,一天两次)灌胃盐酸林可霉素(3g/kgBW)。建立ADD模型后,空白组和模型组灌相同剂量的无菌生理盐水,鼠李糖乳杆菌(LGG)对照组和AUI2301实验组灌相同剂量的含该组受试菌的菌悬液,连续干预6天(10μL/g,一天一次)。
(2)对抗生素相关性腹泻小鼠粪便含水量的影响
如图5和表7所示,与模型组相比,AUI2301实验组的粪便含水量率先恢复正常,说明本发明菌株AUI2301能够缓解腹泻状况。
表7AUI2301对小鼠粪便含水量的影响
组别 | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
空白组 | 59 | 60.5 | 61.1 | 60.2 | 58.6 | 60.5 | 59.2 | 61.2 | 60.7 | 60.6 |
模型组 | 58 | 72.6 | 68.2 | 68.8 | 66.4 | 65.3 | 64.5 | 63 | 61.8 | 61 |
LGG对照组 | 60 | 68.5 | 68.6 | 68.7 | 64.7 | 65 | 64.6 | 65.5 | 62.1 | 61.7 |
AUI2301实验组 | 56.5 | 71 | 71.6 | 68.6 | 63.2 | 63.7 | 62 | 62.9 | 62.5 | 62.7 |
(3)对抗生素相关性腹泻小鼠器官指数的影响
如图6和表8所示,模型组小鼠的盲肠指数为3.19±0.06%,显著高于空白组1.73±0.07%(p<0.01),AUI2301实验组和LGG对照组干预后的盲肠指数下降到1.96±0.11%和2.18±0.14%,而AUI2301无明显差异(p>0.05),说明本发明菌株能够有效缓解部分器官的损伤。
表8AUI2301对盲肠指数的影响
组别 | 盲肠指数(%) |
空白组 | 1.78±0.07c |
模型组 | 3.19±0.06a |
LGG对照组 | 2.18±0.14b |
AUI2301实验组 | 1.96±0.11bc |
实施例7菌株的鉴定
分别观察菌落形态和镜检形态,如图7和图8所示。
菌株16S rDNA测序鉴定:以菌株AUI2301的基因组DNA作为PCR的扩增模板,采用通用16S rDNA引物进行PCR扩增;电泳检测扩增产物后,
送至生工生物工程(上海)股份有限公司进行测序。将测序得到的序列提交
BLAST进行比对分析,如SEQ ID NO:1所示结果见表9。
表916S rDNA对比结果
菌株 | 菌种 | 同源性 |
AUI2301 | 动物双歧杆菌(Bifidobacteriumanimalis) | 100% |
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis),其特征在于,其保藏编号为:CGMCCNo.26770。
2.微生物菌剂,其特征在于,包括如权利要求1所述的动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)以及可接受的助剂。
3.如权利要求1所述的动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或如权利要求2所述的微生物菌剂在制备干预和/或治疗功能性便秘的产品中的应用。
4.如权利要求3所述的应用,其特征在于,所述动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或所述微生物菌剂改善排便状态和/或缩短排便时间。
5.如权利要求3或4所述的应用,其特征在于,所述动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或所述微生物菌剂促进兴奋性神经递质AchE的分泌和/或降低抑制性神经递质NO的分泌。
6.如权利要求3至5任一项所述的应用,其特征在于,所述动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或所述微生物菌剂松弛平滑肌和/或促进胃肠道运动。
7.如权利要求1所述的动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或如权利要求2所述的微生物菌剂在制备干预和/或治疗抗生素相关腹泻的产品中的应用。
8.如权利要求7所述的应用,其特征在于,所述动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或所述微生物菌剂缓解腹泻状态和/或与所述抗生素相关腹泻的器官的损伤。
9.产品,其特征在于,包括如权利要求1所述的动物双歧杆菌乳亚种(Bifidobacteriumanimalissubsp.lactis)和/或如权利要求2所述的微生物菌剂以及可接受的助剂或辅料。
10.如权利要求9所述的产品,其特征在于,包括:益生菌制品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310741822.4A CN116790431A (zh) | 2023-06-21 | 2023-06-21 | 能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310741822.4A CN116790431A (zh) | 2023-06-21 | 2023-06-21 | 能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116790431A true CN116790431A (zh) | 2023-09-22 |
Family
ID=88037184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310741822.4A Pending CN116790431A (zh) | 2023-06-21 | 2023-06-21 | 能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116790431A (zh) |
-
2023
- 2023-06-21 CN CN202310741822.4A patent/CN116790431A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11116806B2 (en) | Composite probiotic lactic acid bacteria powder and preparation method and use thereof | |
CN113088463B (zh) | 一种具有益生特性的嗜酸乳杆菌及其应用 | |
CN110577912B (zh) | 一种格氏乳杆菌及其在制备发酵乳中的应用 | |
CN114990011B (zh) | 一种能够降胆固醇及抑制加德纳菌的罗伊氏乳杆菌和应用 | |
CN113832077B (zh) | 鼠李糖乳杆菌及其应用 | |
CN110564638A (zh) | 一株具有益生特性的罗伊氏乳杆菌及其用途 | |
CN113122466B (zh) | 粪肠球菌及其应用 | |
CN116083324B (zh) | 一种能够改善或治疗肠易激综合征的动物双歧杆菌乳亚种ba79及其培养方法和应用 | |
US11376289B2 (en) | Composition and uses thereof | |
CN114774315B (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
CN114806978B (zh) | 约氏乳杆菌sxdt-23及其应用 | |
CN113122467A (zh) | 一种副干酪乳杆菌及其组合物 | |
CN114480231A (zh) | 一种抗幽门螺杆菌感染的罗伊氏乳杆菌及其应用 | |
CN116286551A (zh) | 长双歧杆菌婴儿亚种在调节体内脂肪代谢、塑形减脂改善肥胖方面的应用 | |
CN115029260A (zh) | 一种具有抗炎及抗氧化特性的格氏乳杆菌及应用 | |
CN112239739B (zh) | 一株可缓解etec致腹泻的植物乳杆菌及其应用 | |
CN111743158B (zh) | 一种具有增强免疫功能的益生菌片剂及其制备方法 | |
CN117004503B (zh) | 一株唾液联合乳杆菌mb1及其在制备助睡眠和调理肠胃食品药品中的应用 | |
CN116445356A (zh) | 一种调节肠道菌群及增强免疫力的动物双歧杆菌乳亚种ba67及其应用 | |
CN114806953B (zh) | 一种具有改善1型糖尿病特性的格氏乳杆菌 | |
CN116179443A (zh) | 一株缓解便秘的乳酸片球菌nss0302及其应用 | |
CN116790431A (zh) | 能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用 | |
CN116790432A (zh) | 能够改善肠道健康的母乳源植物乳杆菌、微生物菌剂及其应用 | |
CN117143767B (zh) | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 | |
CN114317310B (zh) | 一种抗过敏的婴儿双歧杆菌制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |